Welcome to our dedicated page for Cannapharmarx SEC filings (Ticker: CPMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking biological asset fair values, yield per gram, and shifting cannabis regulations across three continents makes CannapharmaRx’s SEC reports anything but straightforward. Their latest filings span hundreds of pages, and investors often ask, “Where can I find CannapharmaRx quarterly earnings report 10-Q filing?” or “How do I monitor CannapharmaRx insider trading Form 4 transactions?”
Stock Titan’s AI-powered analysis cuts through the complexity. The moment a CannapharmaRx 8-K material event posts, our platform delivers real-time alerts and plain-English explanations. We hyperlink every note inside the CannapharmaRx annual report 10-K simplified, highlight EBITDA shifts in each CannapharmaRx earnings report filing analysis, and surface CannapharmaRx executive stock transactions Form 4 so you can see who’s buying or selling—without sifting through dense footnotes.
Whether you’re comparing cultivation cost trends, assessing Israeli export revenue, or checking the CannapharmaRx proxy statement executive compensation, you’ll find every document—10-K, 10-Q, 8-K, S-1, plus CannapharmaRx Form 4 insider transactions real-time—indexed and explained. Use our platform to:
- Track cultivation yield improvements quarter over quarter
- Identify regulatory risks before they affect valuation
- Receive instant alerts on CannapharmaRx insider trading Form 4 transactions
Start understanding CannapharmaRx SEC documents with AI today—every CannapharmaRx 8-K material events explained alongside historical context and trend charts. CannapharmaRx SEC filings explained simply so you make informed decisions faster.
CannaPharmaRx (CPMD) filed its Q3 2025 report, showing rising sales but continued losses and severe liquidity strain. Revenue reached $656,606 in the quarter (up from $312,164), yet the company posted a gross loss of $440,000 and a net loss of $1,477,811. For the nine months, revenue was $1,223,533 with a net loss of $3,581,863. Cash was $927, total liabilities were $34,133,650, and shareholders’ deficit was $22,516,743. Management disclosed substantial doubt about the company’s ability to continue as a going concern.
On August 7, 2025, the company formalized repayment plans with Koze and affiliates and with Mr. Tal: as of June 30, 2025, about $10 million was owed to Koze and about $0.7 million to Mr. Tal, with interest revised to 6% per annum and 60% of all future profits and capital raised allocated toward repayment. The company is also in default under a royalty/security agreement tied to cannabis sales; Koze agreed to forbear until December 31, 2025. Operations rely on a Formosa lease, with unpaid lease amounts accumulating and a related promissory note now at 6%. Shares outstanding were 662,501,405 as of November 14, 2025.
FAQ
What is the current stock price of Cannapharmarx (CPMD)?
What is the market cap of Cannapharmarx (CPMD)?
